Meclofenoxate (also known as centrophenoxine and sold under the brand name Lucidril) is a cholinergic compound and nootropic drug developed in France in the 1950s. It consists of two components chemically combined: dimethylaminoethanol (DMAE) esterified with para-chlorophenoxyacetic acid (pCPA, a synthetic auxin analogue). After absorption, meclofenoxate is hydrolyzed to release DMAE, which is then converted to choline in the body, providing the cholinergic effects associated with the compound. The pCPA component may independently modulate lipid metabolism and act on the central nervous system through mechanisms that are not yet fully characterized.
Meclofenoxate occupies a distinctive position in the nootropic landscape as a compound with a long clinical history in Eastern Europe — particularly in the USSR, East Germany, and Hungary — for treating age-related cognitive decline, cerebrovascular insufficiency, and what Soviet-era medicine termed "cerebral senility." This clinical background gives it a more established historical track record than many newer nootropic compounds, though the quality of older clinical trials does not meet modern evidence standards. It was one of the first compounds to demonstrate reduction of lipofuscin — the cellular "aging pigment" that accumulates in neurons over time — which generated significant scientific interest in the 1960s–1980s regarding its potential anti-aging properties.
In contemporary nootropic practice, meclofenoxate is valued primarily as a choline source for acetylcholine synthesis, with a reputation for slightly better brain penetration than simple choline salts. Some users report a mild stimulant quality from the DMAE component. Its important contraindications — depression, mania, epilepsy, and convulsive disorders — distinguish it from more freely used choline sources and require attention.